lasconde_28_06

53 / 156

865
[DELIRIUM EN EL PACIENTE ONCOLÓGICO- Dr. Cristián Fuentes y cols.]
reversible posterior leukoencephalopathy syndrome in a bladder
cancer patient. Int J Clin Oncol. 2010 Oct;15(5):508-11.
64. Breitbart W, Alici Y. Evidence-based treatment of delirium in
patients with cancer. J Clin Oncol. 2012 Apr 10;30(11):1206-14.
65. Schneider LS, Dagerman KS, Insel P: Risk of death with atypical
antipsychotic drug treatment for dementia: Meta-analysis
of randomized placebo controlled trials. JAMA. 2005 Oct
19;294(15):1934-43.
66. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon
DH, et al: Risk of death in elderly users of conventional vs
atypical antipsychotic medications. N Engl J Med. 2005 Dec
1;353(22):2335-41.
67. US Food and Drug Administration: Information for healthcare
professionals: Conventional Antipsychotics.
drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsand
providers/ucm124830.htm
68. Candy B, Jackson KC, Jones L, Leurent B, Tookman A, King M. Drug
therapy for delirium in terminally ill adult patients. Cochrane
Database Systematic. Reviews Issue 11 2012. Art. No.: CD004770
69. Lindqvist O, Lundquist G, Dickman A, Bükki J, Lunder U, Hagelin
CL, et al. OPCARE9. Four essential drugs needed for quality care
of the dying: aDelphi-study based international expert consensus
opinion. J Palliat Med. 2013 Jan;16(1):38-43
70. Crawford GB, Agar M M, Quinn SJ, Phillips J, Litster C, Michael N,
et al. Pharmacovigilance in hospice/palliative care: net effect of
haloperidol for delirium. J Palliat Med. 2013 Nov;16(11):1335-41
71. Boettger S, Campion P, Breitbart W, Boettger S. The phenomenology
of delirium and its motoric subtypes in patients with cancer. Ger.
J. Psychiatry 2001 March, (14), 66–71.
72. Hatta K1, Kishi Y, Wada K, Odawara T, Takeuchi T, Shiganami T, et
al. Antipsychotics for delirium in the general hospital setting in
consecutive 2453 inpatients: a prospective observational study.
Int J Geriatr Psychiatry. 2014 Mar;29(3):253-62.
73. Prommer E. Olanzapine: palliative medicine update. Am J Hosp
Palliat Care. 2013 Feb;30(1):75-82
74. Breitbart W, Tremblay A, Gibson C. An open trial of olanzapine
for the treatment of delirium in hospitalized cancer patients.
Psychosomatics. 2002 May-Jun;43(3):175-82
75. Mittal D, Jimerson NA, Neely EP, Johnson WD, Kennedy RE,
Torres RA, et al. Risperidone in the treatment of delirium: results
from a prospective open-label trial. J Clin Psychiatry. 2004
May;65(5):662-7.
76. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of
delirium. J Hosp Med. 2013 Apr;8(4):215-20.
77. Tahir TA, Eeles E, Karapareddy V, Muthuvelu P, Chapple S, Phillips
B, et al. A randomized controlled trial of quetiapine versus
placebo in the treatment of delirium. J Psychosom Res. 2010
Nov;69(5):485-90
78. Overshott R, Karim S, Burns, A. Cholinesterase inhibitors for
delirium. Cochrane Database of Systematic Reviews, Issue 1. Art.
No.: CD005317
79. Van Eijk MM, Roes KC, Honing ML, Kuiper MA, Karakus A, van der
Jagt M. et al. Effect of rivastigmine as an adjunct to usual care
with haloperidol on duration of delirium and mortality in critically
ill patients: a multicentre, double-blind, placebo-controlled
randomised trial. Lancet. 2010 Nov 27;376(9755):1829-37.
80. Tahir TA. A review for usefulness of atypical antipsychotics and
cholinesterase inhibitors in delirium. Pharmacopsychiatry. 2012
Jun;45(4):163
81. Agar MR, Lawlor PG, Quinn S, Draper B, Caplan GA, Rowett D, et al.
Efficacy of Oral Risperidone, Haloperidol, or Placebo for Symptoms
of Delirium Among Patients in Palliative Care: A Randomized
Clinical Trial. JAMA Intern Med. 2017 Jan 1;177(1):34-42.